These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. For research use only.  Legal & Disclaimer

GLP-1 Receptor Agonist · Research Compound

Semaglutide Research Compound

Synthetic GLP-1 receptor agonist analog — 34 amino acids with C18 fatty diacid chain. Third-party tested via Krause Analytical, reviewed by Sabrina Runbeck, PA-C. Available in five vial sizes for licensed researchers and qualified practitioners.

5 Vial Sizes: 5mg–30mg
Krause Analytical COA
Sabrina Runbeck, PA-C
Finnrick Pulse Verified
≥99% Purity
Research Use Only — Not for Human Use

Research-grade semaglutide is not Ozempic or Wegovy. Ozempic® and Wegovy® are FDA-approved pharmaceutical drugs manufactured by Novo Nordisk under regulated pharmaceutical conditions. Sequence Labs semaglutide is a research-grade synthetic analog supplied exclusively for in vitro and preclinical laboratory research purposes. It is not approved by the FDA, not intended for human use, and must not be administered to any person.

Compound Identity

What Is Semaglutide?

Semaglutide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist analog composed of 34 amino acids. It was developed by Novo Nordisk as a long-acting GLP-1 analog and received first FDA approval in 2017 under the brand name Ozempic for a specific clinical indication, followed by approval of Wegovy in 2021 under a separate indication.

The compound's molecular architecture is derived from native GLP-1(7–37), a naturally occurring incretin hormone. Semaglutide differs from native GLP-1 through two key structural modifications: a substitution at position 8 (replacing alanine with Aib, α-aminoisobutyric acid) to resist DPP-4 enzymatic cleavage, and the attachment of a C18 fatty diacid chain via a linker at lysine-26. This acylation enables albumin binding in plasma, dramatically extending the compound's half-life from the minutes seen with native GLP-1 to approximately one week.

Molecular specifications: Semaglutide is a 34-amino-acid synthetic peptide (C₁₈₇H₂₉₁N₄₅O₅₉, MW ≈ 4,113.58 Da) featuring a C18 fatty diacid moiety attached via an OEG-OEG-gamma-Glu-mini-PEG linker at Lys²⁶. CAS: 910463-68-2.

  • Class: GLP-1 receptor agonist (GLP-1RA) — long-acting synthetic incretin analog
  • Origin: Developed by Novo Nordisk; structurally derived from human GLP-1(7–37)
  • Structural modification: Position-8 Aib substitution plus C18 fatty diacid chain for albumin binding
  • Sequence origin: 94% sequence homology to human GLP-1; altered at 2 positions relative to natural sequence
  • Research form: Supplied lyophilized (white to off-white powder) for research sample preparation

Published Research

Research Background

Semaglutide is among the most extensively studied GLP-1 receptor agonists in published scientific literature, with hundreds of peer-reviewed studies examining its receptor binding properties, incretin signaling mechanisms, and effects in various preclinical and in vitro models. The research interest spans multiple biological systems where GLP-1 receptors are expressed.

GLP-1 Receptor Binding
Published research has examined receptor binding kinetics, agonist potency, and G-protein coupling at the GLP-1R.
Incretin Signaling Pathways
Peer-reviewed studies have investigated cAMP second-messenger cascades and downstream signaling downstream of GLP-1R activation.
Pancreatic Beta-Cell Studies
Research has examined the role of GLP-1R agonism in pancreatic islet cell function and beta-cell proliferation models.
Gastric Motility Research
Published studies have investigated GLP-1R-mediated regulation of gastric emptying and gastrointestinal motility at the cellular level.
CNS Peptide Receptor Studies
Research has examined GLP-1R expression in central nervous system regions including hypothalamus, brainstem, and areas of reward circuitry.
View semaglutide publications on PubMed →

Sequence Labs Supply

Available Sizes, Testing & COA

Sequence Labs offers research-grade semaglutide in five lyophilized vial sizes. Every batch undergoes independent third-party testing through Krause Analytical in Austin, TX, with batch-specific COAs publicly accessible and verifiable via Finnrick Pulse.

Size Price Form COA Stock
5 mg $43.99 Lyophilized vial Batch COA In Stock
10 mg $70.99 Lyophilized vial Batch COA In Stock
15 mg $97.99 Lyophilized vial Batch COA In Stock
20 mg $128.99 Lyophilized vial Batch COA In Stock
30 mg $148.99 Lyophilized vial Batch COA In Stock
HPLC
Identity & Purity
MS
Mass Spec Verified
≥99%
Verified Purity
3rd Party
Krause Analytical
PA-C
Catalog Review

Wholesale available. Licensed practitioners, compounding pharmacies, medical spas, and research institutions can apply for tiered B2B pricing — typically 18–32% below retail with no monthly commitment. View wholesale terms →

Research Preparation

Reconstitution Reference

The following describes standard laboratory procedures for preparing lyophilized research samples. This information is provided for qualified laboratory personnel. For research use only — not for human use.

  1. Inspect the vial. Confirm the vial seal is intact. Inspect the lyophilized research sample visually — it should appear as a white to off-white powder or cake. Verify the batch number against your COA from Krause Analytical.
  2. Select appropriate solvent. Bacteriostatic water (BAC water, 0.9% benzyl alcohol) is the most commonly used solvent for lyophilized peptide research samples. Use only sterile, research-grade solvent appropriate to your laboratory protocol.
  3. Introduce solvent to the vial. Using a sterile syringe, introduce the calculated volume of solvent slowly along the inner wall of the vial. Do not inject solvent directly onto the lyophilized cake.
  4. Allow to dissolve. Gently swirl — do not vortex or shake vigorously. Allow the lyophilized material to dissolve fully, which typically takes 1–3 minutes for semaglutide research preparations.
  5. Storage of reconstituted research sample. Store the reconstituted research preparation at 2–8°C (refrigerated) and use within the timeframe appropriate to your research protocol. Lyophilized (unreconstituted) vials should be stored at -20°C per COA instructions.

For research use only. All preparation and handling procedures must comply with applicable institutional, state, and federal regulations governing research compound handling. Sequence Labs provides this reference for laboratory informational purposes only.

Frequently Asked Questions

Semaglutide Research FAQ

Research-grade semaglutide is a synthetic GLP-1 receptor agonist analog supplied exclusively for in vitro and preclinical research purposes. It is not FDA-approved, not formulated for human use, and is not the same product as Ozempic or Wegovy. Ozempic and Wegovy are FDA-approved pharmaceutical drugs manufactured by Novo Nordisk under strictly regulated conditions with defined clinical indications. Sequence Labs research-grade semaglutide is intended only for licensed researchers and qualified practitioners conducting laboratory research, not for administration to any person.
Sequence Labs offers semaglutide research compound in five vial sizes: 5mg ($43.99), 10mg ($70.99), 15mg ($97.99), 20mg ($128.99), and 30mg ($148.99). All sizes are lyophilized and supplied with batch-specific COA documentation from Krause Analytical. Wholesale pricing is available for licensed practitioners and institutions.
Every batch of Sequence Labs semaglutide is independently tested by Krause Analytical (Austin, TX) — a third-party laboratory — using both HPLC and mass spectrometry for identity, purity, and potency verification. Batch-specific Certificates of Analysis (COAs) are publicly accessible and verifiable via the Finnrick Pulse platform. The full catalog is also reviewed by a licensed PA-C for research integrity.
Yes. Licensed practitioners, medical spas, research institutions, and compounding pharmacies can access tiered wholesale pricing through Sequence Labs' gated B2B portal. Tiered discounts range from approximately 18% to 32% below retail with no monthly commitment. Contact Team@SequenceLabs.Health or visit the wholesale page to apply.
The glucagon-like peptide-1 (GLP-1) receptor is a G protein-coupled receptor expressed in pancreatic beta cells, the central nervous system, the gastrointestinal tract, and other tissues. It plays a critical role in incretin signaling pathways. Semaglutide is a synthetic GLP-1 receptor agonist analog modified with a C18 fatty diacid chain to extend its plasma half-life versus native GLP-1. Research interest in semaglutide centers on GLP-1 receptor binding mechanisms, pancreatic beta-cell function, gastric motility regulation, and CNS peptide receptor studies — making it one of the most-studied incretin analogs in peer-reviewed literature, with hundreds of indexed publications on PubMed.

Ready to Order?

Research-grade semaglutide, verified and in stock

Five sizes, batch COA from Krause Analytical, reviewed by reviewed by Sabrina Runbeck, PA-C. Order direct or apply for wholesale pricing.